Literature DB >> 24743141

Repurposing staples for viruses: applying peptide design to RSV prophylaxis.

Sarah P Katen, Terence S Dermody.   

Abstract

Respiratory syncytial virus (RSV) is responsible for lower respiratory tract infections and annually results in 200,000 deaths worldwide. Despite the burden of RSV-associated disease, treatments and preventative measures are limited. In this issue of JCI, Bird and colleagues describe their work using a peptide stapling technique that allowed synthesis of a stable peptide mimic of a portion of the RSV fusion protein. Pretreatment of cells with the stable peptide effectively blocked virus entry. When introduced into mice prior to RSV exposure, the peptide produced a substantial prophylactic effect. This work provides a new way forward in RSV prevention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743141      PMCID: PMC4001561          DOI: 10.1172/JCI75797

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

2.  Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.

Authors:  Jason S McLellan; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

3.  RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein.

Authors:  V Razinkov; A Gazumyan; A Nikitenko; G Ellestad; G Krishnamurthy
Journal:  Chem Biol       Date:  2001-07

4.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

Authors:  D M Lambert; S Barney; A L Lambert; K Guthrie; R Medinas; D E Davis; T Bucy; J Erickson; G Merutka; S R Petteway
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

5.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

6.  Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection.

Authors:  Gregory H Bird; Sandhya Boyapalle; Terianne Wong; Kwadwo Opoku-Nsiah; Raminder Bedi; W Christian Crannell; Alisa F Perry; Huy Nguyen; Viviana Sampayo; Ankita Devareddy; Subhra Mohapatra; Shyam S Mohapatra; Loren D Walensky
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

7.  Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Tomas Cihlar
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 8.  Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Authors:  Tea Andabaka; Jason W Nickerson; Maria Ximena Rojas-Reyes; Juan David Rueda; Vesna Bacic Vrca; Bruno Barsic
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

9.  Respiratory syncytial viral infection in children with compromised immune function.

Authors:  C B Hall; K R Powell; N E MacDonald; C L Gala; M E Menegus; S C Suffin; H J Cohen
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

Review 10.  Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.

Authors:  Gregory B Melikyan
Journal:  Retrovirology       Date:  2008-12-10       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.